KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 102 filers reported holding KALA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $242,000 | -58.2% | 175,000 | +11.5% | 0.01% | -37.5% |
| Q4 2019 | $579,000 | -3.0% | 156,900 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $597,000 | -32.2% | 156,900 | +13.7% | 0.01% | -27.3% |
| Q2 2019 | $880,000 | -22.9% | 138,000 | 0.0% | 0.01% | -21.4% |
| Q1 2019 | $1,141,000 | +174.3% | 138,000 | +62.4% | 0.01% | +133.3% |
| Q4 2018 | $416,000 | -50.4% | 85,000 | 0.0% | 0.01% | -25.0% |
| Q3 2018 | $839,000 | – | 85,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,142,360 | $7,745,000 | 4.83% |
| RA Capital Management | 10,874,613 | $73,730,000 | 1.03% |
| Mesirow Financial Investment Management, Inc. | 43,431 | $294,462,000 | 0.93% |
| Parkman Healthcare Partners LLC | 272,445 | $1,847,000 | 0.47% |
| Samsara BioCapital, LLC | 601,162 | $4,076,000 | 0.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $693,000 | 0.40% |
| Eventide Asset Management | 3,450,000 | $23,391,000 | 0.36% |
| Orbimed Advisors | 5,465,030 | $37,053,000 | 0.32% |
| Vivo Capital, LLC | 786,883 | $5,335,000 | 0.24% |
| Knights of Columbus Asset Advisors LLC | 169,429 | $1,149,000 | 0.12% |